New drug combo shows promise for blood cancers in early trial

NCT ID NCT00392353

First seen Feb 19, 2026 · Last updated May 08, 2026 · Updated 10 times

Summary

This study tested a combination of two drugs, vorinostat and azacitidine, in 135 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find the safest dose and see how well the drugs work together to stop cancer cell growth. Participants received the drugs in cycles, and researchers tracked side effects and how many patients responded to treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, 10467, United States

  • Montefiore Medical Center-Weiler Hospital

    The Bronx, New York, 10461, United States

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • North Shore University Hospital

    Manhasset, New York, 11030, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland, 21201, United States

Conditions

Explore the condition pages connected to this study.